Difference between revisions of "Part:BBa K4165144"
Line 38: Line 38:
  
 
===References===
 
===References===
−
1. Reference
+
1. Seidler, P. M., Boyer, D. R., Rodriguez, J. A., Sawaya, M. R., Cascio, D., Murray, K., ... & Eisenberg, D. S. (2018). Structure-based inhibitors of tau aggregation. Nature chemistry, 10(2), 170-176.
  
  

Revision as of 18:20, 5 October 2022


MINK Peptide

Tau binding peptide targeting the PHF seed of Tau

Usage and Biology

MINK is a peptide with amino acid sequence of DVQMINKKRK, it is designed to inhibit the fibrillization of tau which is one of the main drivers of Alzheimer’s disease and other dementia diseases. PHF* (VQIINK) is the site that derives tau aggregation. MINK can bind to PHF* in a mean that can disrupt the interface between each PHF* and consequently reduce the aggregates. Its IC50 for inhibition of tau aggregates were 22.6 μM.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]

Dry Lab

Modeling

MINK is modeled by AlphaFold2, Apptest, ITAsser and TrRosetta, best model obtained from Apptest 



                            Figure 1.: Predicted 3D structure of Synthetic peptide MINK.


Table 1: Quality assessment parameters of MINK model.


References

1. Seidler, P. M., Boyer, D. R., Rodriguez, J. A., Sawaya, M. R., Cascio, D., Murray, K., ... & Eisenberg, D. S. (2018). Structure-based inhibitors of tau aggregation. Nature chemistry, 10(2), 170-176.